ClinicalTrials.gg
CompletedNCT05917782Updated Oct 31, 2023

A Study to Evaluate the Pharmacokinetics Similarity of CBP-201 in Healthy Adult Chinese Subjects

A Phase 1 interventional study of Test drug (T1): CBP-201 injection (pre-filled syringe, 150 mg/1 mL) and Test drug (T2): CBP-201 injection (pre-filled syringe, 300 mg/2 mL) in Healthy Adult Subjects, sponsored by Connect Biopharm LLC. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-10-31.

Sponsored by Connect Biopharm LLC · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
324
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This is a single-center, randomized, open-label, single-dose, parallel-designed PK similarity study.

Read the detailed description

A total of 324 healthy subjects are planned to be enrolled and randomized into 3 groups at a ratio of 1:1:1, with 108 subjects in each group. They will receive 2 doses of the test drug T1 (CBP-201 injection (pre-filled syringe, 150 mg/1 mL)), 1 dose of the test drug T2 (CBP-201 injection (pre-filled syringe, 300 mg/2 mL)), and 2 doses of the reference drug R (CBP-201 injection (vial, 150 mg/1 mL)), respectively.

The study consists of a screening period (Day-28 to Day-2), a baseline period (Day-1), an administration and observation period (Day1 to Day6), and a follow-up period (Day7 to Day57).

02

Conditions studied

  • Healthy Adult Subjects
03

In context

Lead sponsor

Connect Biopharm LLC is the lead sponsor of 11 studies on the registry; 1 is open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 4 (57%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects who are to read, understand, and sign the ICF.
  2. Healthy adult male or female subjects aged 18-45 years (inclusive) at screening, with each sex accounting for at least one-third of the overall sample size.
  3. (BMI) is between 19 and 28 kg/m2 (inclusive). Male subjects weigh ≥ 50 kg, and female subjects weigh ≥ 45 kg.
  4. Subjects with partners must agree to take medically accepted effective measures (including physical contraception, surgery, abstinence, etc) from signing of the ICF until 90 days after administration.
  5. The results of vital sign assessment, physical examination, clinical laboratory tests (hematology, urinalysis, biochemistry, coagulation) and 12-lead at screening or baseline are normal or abnormal but not .
  6. Subjects who are able to communicate well with the clinical staff and complete the study according to the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Subjects who have diseases or conditions with abnormal clinical manifestations, including but not limited to renal, cardiac, hematological, bronchial, pulmonary, vascular, gastrointestinal, allergic, neurological, endocrine and metabolic diseases (diabetes mellitus, thyroid disorder, and adrenal disorder), skeletal disease and immunodeficiency, cancer, and hepatitis, or cirrhosis.
  2. Subjects with allergic diseases (such as allergic rhinitis, allergic asthma) at screening, a history of systemic anaphylaxis, or who may be allergic to any component of the test drugs or similar drugs as determined by the investigator.
  3. Subjects who have donated blood or have had substantial loss of blood (> 400 mL) within 3 months before administration.
  4. Subjects who have been vaccinated with live (attenuated) vaccines within 3 months before administration.
  5. Subjects who have participated in clinical studies of other drugs within 3 months before administration.
  6. Subjects who have taken any prescription drugs, over-the-counter drugs, vitamin products, Chinese patent medicines, and Chinese herbal medicines within 1 month before administration.
  7. Subjects who have been diagnosed with diseases or have undergone major surgical procedures within 1 month before administration, or who are scheduled to undergo major surgery during the study.
  8. Female subjects who test positive for pregnancy at screening or baseline or who are lactating.
  9. Subjects who smoke more than 5 cigarettes or equivalent per day within 3 months before administration.
  10. Subjects who have a history of drug abuse within the last 5 years, who have used narcotics within 3 months before administration, or who test positive in urine drug screening at the screening/baseline visit.
  11. Subjects who have a history of regular alcohol consumption, which is defined as consumption of more than 7 units of alcohol per week for females or more than 14 units of alcohol per week for males (1 unit of alcohol equals 360 mL of beer, 45 mL of 40% liquor, or 150 mL of wine) within 3 months before administration, who take any alcohol-containing product within 48 h before administration, or who test positive in blood alcohol tests at the screening/ baseline visit.
  12. Subjects with known symptoms of dermatitis or skin abnormalities at and around the site of administration.
  13. Subjects who test positive for treponema pallidum antibody (TP-Ab), surface antigen (HBsAg), hepatitis B core antibody (HBcAb) or virus antibody (HCV-Ab), and antibody (HIV-Ab).
  14. Patients with active tuberculosis, latent tuberculosis, or nontuberculous mycobacterial infection at screening;

    Notes:

    • Unless treatment records clearly documented by a specialist demonstrate that the patients have been adequately treated and may begin treatment with biological product (based on the medical judgment by the investigator and/or infectious disease specialist);
    • If needed, T-spot tests may be used to assist diagnosis of suspected tuberculosis.
  15. Subjects with white blood cell count and below the lower limit of normal.
  16. Female subjects with values less than 110 g/L or male subjects less than 120 g/L.
  17. Subjects who cannot tolerate venous blood sampling, or who have a history of acupuncture syncope or hemophobia.
  18. Subjects who still need or plan to engage in strenuous physical activity or exercise during the study.
  19. Any other conditions that the investigator determines may affect the subject's provision of or compliance with the study protocol, or that the investigator deems unsuitable for participation in this study, or the subjects' participation in the study may affect the study results or their own safety.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
324 participants (actual)

Study arms

  • Experimental
    Test drug (T1): CBP-201 injection (pre-filled syringe, 150 mg/1 mL)

    Strength: pre-filled syringe, 150 mg/1 mL

    Biological: Test drug (T1): CBP-201 injection (pre-filled syringe, 150 mg/1 mL)

  • Experimental
    Test drug (T2): CBP-201 injection (pre-filled syringe, 300 mg/2 mL)

    Strength: pre-filled syringe, 300 mg/2 mL

    Biological: Test drug (T2): CBP-201 injection (pre-filled syringe, 300 mg/2 mL)

  • Active comparator
    Reference drug (R): CBP-201 injection (vial, 150 mg/1 mL)

    Strength: vial, 150 mg/1 mL

    Biological: Reference drug (R): CBP-201 injection (vial, 150 mg/1 mL)

Interventions

  • BiologicalTest drug (T1): CBP-201 injection (pre-filled syringe, 150 mg/1 mL)

    Drug page: CBP-201

    subcutaneous injection of 2 doses on Day 1

  • BiologicalTest drug (T2): CBP-201 injection (pre-filled syringe, 300 mg/2 mL)

    Drug page: CBP-201

    subcutaneous injection of 1 dose on Day 1

  • BiologicalReference drug (R): CBP-201 injection (vial, 150 mg/1 mL)

    Drug page: CBP-201

    subcutaneous injection of 2 doses on Day 1

06

What researchers measure

Primary outcomes

  1. Cmax: Maximum concentration

    Pharmacokinetics similarity evaluation for test drug T1, test drug T2 and reference drug R

    Time frame: Pre-dose and 6hour, 24hour, 48hour, 72hour, 96hour, 120hour, Day8, Day10, Day11, Day12, Day15, Day18, Day22, Day29, Day36, Day43, Day57 post-dose

  2. AUC0-t: Area under the plasma concentration-time curve from the start of administration to the last measurable concentration time point T

    Pharmacokinetics similarity evaluation for test drug T1, test drug T2 and reference drug R

    Time frame: Pre-dose and 6hour, 24hour, 48hour, 72hour, 96hour, 120hour, Day8, Day10, Day11, Day12, Day15, Day18, Day22, Day29, Day36, Day43, Day57 post-dose

  3. AUC0-inf: Area under the plasma concentration-time curve from the start of administration to infinity

    Pharmacokinetics similarity evaluation for test drug T1, test drug T2 and reference drug R

    Time frame: Pre-dose and 6hour, 24hour, 48hour, 72hour, 96hour, 120hour, Day8, Day10, Day11, Day12, Day15, Day18, Day22, Day29, Day36, Day43, Day57 post-dose

Secondary outcomes

  1. Maximum concentration (Cmax)

    Calculated by non-compartmental analysis (NCA) using WinNonLin V8.3.1 (or higher version)

    Time frame: Pre-dose and 6hour, 24hour, 48hour, 72hour, 96hour, 120hour, Day8, Day10, Day11, Day12, Day15, Day18, Day22, Day29, Day36, Day43, Day57 post-dose

  2. Area under the plasma concentration-time curve from the start of administration to the last measurable concentration time point T (AUC0-t)

    Calculated by non-compartmental analysis (NCA) using WinNonLin V8.3.1 (or higher version)

    Time frame: Pre-dose and 6hour, 24hour, 48hour, 72hour, 96hour, 120hour, Day8, Day10, Day11, Day12, Day15, Day18, Day22, Day29, Day36, Day43, Day57 post-dose

  3. Area under the plasma concentration-time curve from the start of administration to infinity (AUC0-inf)

    Calculated by non-compartmental analysis (NCA) using WinNonLin V8.3.1 (or higher version)

    Time frame: Pre-dose and 6hour, 24hour, 48hour, 72hour, 96hour, 120hour, Day8, Day10, Day11, Day12, Day15, Day18, Day22, Day29, Day36, Day43, Day57 post-dose

  4. Time to peak (Tmax)

    Calculated by non-compartmental analysis (NCA) using WinNonLin V8.3.1 (or higher version)

    Time frame: Pre-dose and 6hour, 24hour, 48hour, 72hour, 96hour, 120hour, Day8, Day10, Day11, Day12, Day15, Day18, Day22, Day29, Day36, Day43, Day57 post-dose

  5. Elimination half-life (t1/2)

    Calculated by non-compartmental analysis (NCA) using WinNonLin V8.3.1 (or higher version)

    Time frame: Pre-dose and 6hour, 24hour, 48hour, 72hour, 96hour, 120hour, Day8, Day10, Day11, Day12, Day15, Day18, Day22, Day29, Day36, Day43, Day57 post-dose

  6. Apparent clearance (CL/F)

    Calculated by non-compartmental analysis (NCA) using WinNonLin V8.3.1 (or higher version)

    Time frame: Pre-dose and 6hour, 24hour, 48hour, 72hour, 96hour, 120hour, Day8, Day10, Day11, Day12, Day15, Day18, Day22, Day29, Day36, Day43, Day57 post-dose

  7. Apparent volume of distribution (Vz/F)

    Calculated by non-compartmental analysis (NCA) using WinNonLin V8.3.1 (or higher version)

    Time frame: Pre-dose and 6hour, 24hour, 48hour, 72hour, 96hour, 120hour, Day8, Day10, Day11, Day12, Day15, Day18, Day22, Day29, Day36, Day43, Day57 post-dose

  8. Terminal elimination phase rate constant (λz)

    Calculated by non-compartmental analysis (NCA) using WinNonLin V8.3.1 (or higher version)

    Time frame: Pre-dose and 6hour, 24hour, 48hour, 72hour, 96hour, 120hour, Day8, Day10, Day11, Day12, Day15, Day18, Day22, Day29, Day36, Day43, Day57 post-dose

  9. Adverse events (AEs)

    All adverse events will be coded using Medical Dictionary for Regulatory Activities (MedDRA) (the latest version).

    Time frame: Up to 57 days post dosing

  10. Injection site reactions

    The injection site will be examined and the results will be judged by the investigator.

    Time frame: Day1, Day2, Day3, Day4, Day6, Day8, Day15, Day22, Day29, Day57

  11. Blood Pressure (systolic and diastolic blood pressures)

    The results as well as their changes from baseline will be statistically summarized by dose group and visit.

    Time frame: pre-dose, Day1, Day2, Day3, Day4, Day6, Day8, Day10, Day11, Day12, Day15, Day18, Day22, Day29, Day36, Day43, Day57

  12. Pulse

    The results as well as their changes from baseline will be statistically summarized by dose group and visit.

    Time frame: pre-dose, Day1, Day2, Day3, Day4, Day6, Day8, Day10, Day11, Day12, Day15, Day18, Day22, Day29, Day36, Day43, Day57

  13. Body Temperature (ear temperature)

    The results as well as their changes from baseline will be statistically summarized by dose group and visit.

    Time frame: pre-dose, Day1, Day2, Day3, Day4, Day6, Day8, Day10, Day11, Day12, Day15, Day18, Day22, Day29, Day36, Day43, Day57

  14. Respiratory Rate

    The results as well as their changes from baseline will be statistically summarized by dose group and visit.

    Time frame: pre-dose, Day1, Day2, Day3, Day4, Day6, Day8, Day10, Day11, Day12, Day15, Day18, Day22, Day29, Day36, Day43, Day57

  15. Physical examination

    Physical examination items include: skin (including observation of the planned injection site (abdomen) and surrounding skin during the screening period and at baseline), lymph nodes, head, eyes, neck, chest, abdomen, spine/extremities, and nervous system. The results of physical examination will be evaluated by investigator's observation.

    Time frame: pre-dose, Day6, Day15, Day29, Day57

  16. 12-lead electrocardiogram (ECG)

    ECG variables include ventricular heart rate, PR interval, QRS interval, QT interval, and QTcF interval.

    Time frame: pre-dose, Day1, Day2, Day4, Day6, Day10, Day15, Day22, Day29, Day36, Day43, Day57

  17. Clinical laboratory test: Hematology - Hemoglobin (Hgb)

    The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.

    Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57

  18. Clinical laboratory test: Hematology - Hematocrit (Hct)

    The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.

    Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57

  19. Clinical laboratory test: Hematology - red blood cell count (RBC)

    The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.

    Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57

  20. Clinical laboratory test: Hematology - platelet count

    The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.

    Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57

  21. Clinical laboratory test: Hematology - white blood cell count (WBC)

    The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.

    Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57

  22. Clinical laboratory test: Hematology - lymphocyte count

    The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.

    Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57

  23. Clinical laboratory test: Hematology - lymphocyte percentage

    The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.

    Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57

  24. Clinical laboratory test: Hematology - neutrophil count

    The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.

    Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57

  25. Clinical laboratory test: Hematology - neutrophil percentage

    The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.

    Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57

  26. Clinical laboratory test: Hematology - monocyte count

    The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.

    Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57

  27. Clinical laboratory test: Hematology - monocyte percentage

    The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.

    Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57

  28. Clinical laboratory test: Hematology - eosinophil count

    The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.

    Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57

  29. Clinical laboratory test: Hematology - eosinophil percentage

    The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.

    Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57

  30. Clinical laboratory test: Hematology - basophil count

    The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.

    Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57

  31. Clinical laboratory test: Hematology - basophil percentage

    The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.

    Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57

  32. Clinical laboratory test: Hematology - mean corpuscular hemoglobin (MCH)

    The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.

    Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57

  33. Clinical laboratory test: Hematology - mean corpuscular volume (MCV)

    The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.

    Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57

  34. Clinical laboratory test: Urinalysis

    Urine protein, cast, urine red blood cells, urine white blood cells, urine pH, urine ketone body, glucose urine, urine bilirubin, and urine occult blood

    Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57

  35. Clinical laboratory test: Biochemistry - Glucose (Glu)

    The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.

    Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57

  36. Clinical laboratory test: Biochemistry - alanine aminotransferase (ALT)

    The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.

    Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57

  37. Clinical laboratory test: Biochemistry - aspartate aminotransferase (AST)

    The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.

    Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57

  38. Clinical laboratory test: Biochemistry - alkaline phosphatase (ALP)

    The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.

    Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57

  39. Clinical laboratory test: Biochemistry - lactate dehydrogenase (LDH)

    The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.

    Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57

  40. Clinical laboratory test: Biochemistry - gamma-glutamyltransferase (γ-GGT)

    The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.

    Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57

  41. Clinical laboratory test: Biochemistry - serum total protein (TP)

    The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.

    Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57

  42. Clinical laboratory test: Biochemistry - albumin (ALB)

    The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.

    Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57

  43. Clinical laboratory test: Biochemistry - total bilirubin (TBIL)

    The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.

    Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57

  44. Clinical laboratory test: Biochemistry - direct bilirubin (DBIL)

    The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.

    Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57

  45. Clinical laboratory test: Biochemistry - blood urea nitrogen (BUN)

    The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.

    Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57

  46. Clinical laboratory test: Biochemistry - creatinine (Crea)

    The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.

    Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57

  47. Clinical laboratory test: Biochemistry - sodium (Na)

    The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.

    Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57

  48. Clinical laboratory test: Biochemistry - potassium (K)

    The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.

    Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57

  49. Clinical laboratory test: Biochemistry - chlorine (Cl)

    The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.

    Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57

  50. Clinical laboratory test: Biochemistry - calcium (Ca)

    The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.

    Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57

  51. Clinical laboratory test: Biochemistry - phosphorus (P)

    The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.

    Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57

  52. Clinical laboratory test: Biochemistry - triglycerides (TG)

    The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.

    Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57

  53. Clinical laboratory test: Biochemistry - total cholesterol (TC)

    The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.

    Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57

  54. Clinical laboratory test: Biochemistry - high-density lipoprotein cholesterol (HDL-C)

    The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.

    Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57

  55. Clinical laboratory test: Biochemistry - low-density lipoprotein cholesterol (LDL-C)

    The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.

    Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57

  56. Clinical laboratory test: Biochemistry - uric acid (UA)

    The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.

    Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57

  57. Clinical laboratory test: Biochemistry - creatine kinase (CK)

    The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.

    Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57

  58. Clinical laboratory test: Coagulation - International normalized ratio (INR)

    The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.

    Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57

  59. Clinical laboratory test: Coagulation - prothrombin time (PT)

    The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.

    Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57

  60. Clinical laboratory test: Coagulation - activated partial thromboplastin time (APTT)

    The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.

    Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57

  61. Clinical laboratory test: Coagulation - fibrinogen (FIB)

    The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.

    Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57

  62. Clinical laboratory test: Pregnancy test

    Blood pregnancy test (for females only)

    Time frame: pre-dose, Day15, Day29, Day43, Day57

  63. Clinical laboratory test: Infectious serology

    Hepatitis B surface antigen, hepatitis B core antibody, hepatitis C antibody, Treponema pallidum antibody, and human immunodeficiency virus antibody

    Time frame: pre-dose

  64. Clinical laboratory test: Blood alcohol test

    Blood alcohol test

    Time frame: pre-dose

  65. Clinical laboratory test: Urine drug abuse screening

    Morphine, methamphetamine, ketamine, methylenedioxy methylamphetamine, marijuana, and cocaine

    Time frame: pre-dose

  66. T-Spot

    If necessary, T-spot screening can be performed for priorly infected or suspected patients

    Time frame: pre-dose

  67. Immunogenicity: The positive rate and titer of anti-drug antibody (ADA), and the positive rate of neutralizing antibody (Nab, in case of ADA positive results)

    Immunogenicity will be analyzed based on IMS. The number and percentage of subjects positive for CBP-201 ADA and Nab will be summarized by dose group.

    Time frame: pre-dose, Day11, Day29, Day43, Day57

07

Study locations

1 site
  • The Second Hospital of Anhui Medical University
    Hefei, Anhui 230000, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2023 to primary completion in Oct 2023, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2023
First posted
Jun 26, 2023
StartActual
Jul 18, 2023
Primary completionActual
Oct 6, 2023
CompletionActual
Oct 6, 2023
Last update
Oct 31, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 31, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05917782
Lead sponsor
Connect Biopharm LLC
Responsible party
Sponsor
First posted
Jun 26, 2023
Start date
Jul 18, 2023
Primary completion
Oct 6, 2023
Completion
Oct 6, 2023
Last update
Oct 31, 2023

Study contacts

Suzhou Connect
study director · Connect Biopharm LLC

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CBP-201

Start the discussion